HC Wainwright Reiterates Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports.

A number of other brokerages also recently commented on SRPT. Piper Sandler lifted their price objective on shares of Sarepta Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research report on Thursday, October 30th. Bank of America lifted their price target on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an “underperform” rating in a report on Wednesday, October 22nd. Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a research note on Monday, December 29th. Guggenheim cut their price objective on Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Finally, Barclays reduced their target price on Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $33.84.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $22.80 on Tuesday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 2.95. The stock has a 50 day moving average price of $21.22 and a 200 day moving average price of $19.83. The stock has a market capitalization of $2.39 billion, a PE ratio of -7.57, a price-to-earnings-growth ratio of 0.52 and a beta of 0.48. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $120.05.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The company had revenue of $399.36 million for the quarter, compared to the consensus estimate of $331.51 million. During the same quarter in the prior year, the company earned $0.62 EPS. The company’s revenue for the quarter was down 14.5% on a year-over-year basis. Analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares in the company, valued at $4,312,523. The trade was a 6.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Sarepta Therapeutics by 18.1% in the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock valued at $208,452,000 after acquiring an additional 1,657,267 shares in the last quarter. Erste Asset Management GmbH boosted its holdings in Sarepta Therapeutics by 65.7% in the 3rd quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock valued at $50,588,000 after purchasing an additional 1,064,530 shares during the period. Aberdeen Group plc boosted its holdings in Sarepta Therapeutics by 13.6% in the 4th quarter. Aberdeen Group plc now owns 2,251,593 shares of the biotechnology company’s stock valued at $48,454,000 after purchasing an additional 268,829 shares during the period. First Trust Advisors LP grew its position in shares of Sarepta Therapeutics by 209.1% during the 3rd quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock worth $37,380,000 after purchasing an additional 1,312,220 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Sarepta Therapeutics by 3.0% during the second quarter. Geode Capital Management LLC now owns 1,875,997 shares of the biotechnology company’s stock worth $32,085,000 after purchasing an additional 55,076 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Company announcement — Sarepta reported positive topline 3‑year EMBARK results showing ELEVIDYS significantly slows disease progression on key functional measures versus an external control, which drove the immediate market rally. Sarepta Announces Positive Topline Three-Year EMBARK Results
• Positive Sentiment: Analyst/upgrades and media momentum — Coverage from major outlets and a Zacks upgrade to a Buy (Zacks Rank #2) amplified optimism and likely supported buying interest after the readout. Sarepta Therapeutics (SRPT) Upgraded to Buy
• Neutral Sentiment: Valuation check — Analysts and commentators are reassessing SRPT’s valuation after the short‑term share momentum; watch multiples and forward estimates for follow‑through. Assessing Sarepta Therapeutics (SRPT) Valuation
• Neutral Sentiment: Full data/transcript available — A Seeking Alpha transcript and other detailed writeups are available for investors who want drill‑down on endpoints, statistical significance and subgroup effects. These details will matter for longer‑term conviction. EMBARK Phase 3 Transcript
• Negative Sentiment: Citi Sell / safety & label risk — Citi’s Yigal Nochomovitz issued a Sell / high‑risk rating, arguing that safety uncertainty and potential label restrictions could overshadow the positive efficacy data. That bearish stance increases downside risk despite the readout. Sarepta Therapeutics: Safety Uncertainty and Label Risk
• Negative Sentiment: Regulatory / safety backdrop — ELEVIDYS previously faced FDA restrictions to ambulatory patients after acute liver‑injury deaths in non‑ambulatory patients; investors should weigh the readout against this prior safety signal and the potential for labeling or post‑market requirements. Investors Brace for Pivotal Monday Data Release

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.